secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001564590-22-010212
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara reports FY2021 net loss $51.4M; interim Phase 2b data expected April 2022
-------------------------------------------------------------------------------

- Net loss $51.4M ($2.37 per share) vs $49.2M ($3.53 per share) in FY2020; cash $90.3M at Dec 31, 2021.
- Phase 2b SCD and beta-thalassemia trials fully enrolled; interim data from both trials expected first week of April 2022.
- FDA required change of Ardent SCD trial primary endpoint to annualized VOC rate; conduct unchanged.
- Added HFpEF indication for tovinontrine; Phase 2 trial dosing expected Q2 2022; pipeline expanded with IMR-261.
- FY2022 guidance: R&D $60-65M, G&A $13-15M; cash runway through Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000156459022010212/0001564590-22-010212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000156459022010212/imra-8k_20220315.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-010212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer